Description
Data Sheet
| Amino acid sequence | MGSSHHHHHH SSGLVPRGSH MPVSQPDAPG HQRKVVSWID VYTRATCQPR EVVVPLTVEL MGTVAKQLVP SCVTVQRCGG CCPDDGLECV PTGQHQVRMQ ILMIRYPSSQ LGEMSLEEHS QCECRPKKKD SAVKPDRAAT PHHRPQPRSV PGWDSAPGAP SPADITHPTP APGPSAHAAP STTSALTPGP AAAAADAAAS SVAKGGA. |
| Biological Activity | Measured in a cell proliferation assay using NIH-3T3 mouse embryonic fibroblast. The ED50 for this effect is |
| Description | VEGFB Human Recombinant produced in E.Coli is a double, non-glycosylated, polypeptide chain containing 207 amino acids (22-207) and having a molecular mass of 21.6 kDa (molecular weight on SDS-PAGE will appear higher).The VEGFB is fused to a 20 amino acid His Tag at N-terminus & purified by proprietary chromatographic techniques. |
| Expression host | Escherichia Coli. |
| Formulation | The VEGFB protein solution contains 20mM Tris-HCl buffer pH 7.5 & 10% glycerol. |
| Protein Background | VEGFB is a growth factor for endothelial cells. VEGFB 167 a.a. binds heparin and neuropilin-1 while the binding to neuropilin-1 of VEGFB 186 a.a. is regulated by proteolysis. Overexpression of VEGFB in mouse heart alters cardiac lipid metabolism and induces myocardial hypertrophy. Increased VEGFB expression is associated with hepatocellular carcinoma. VEGF-B has restricted angiogenic activity in the ischemic heart. VEGFB binds to VEGFR1, Flt1, but not to VEGFR2 and VEGFR3. VEGFB is homodimeric, heparin-binding glycoprotein involved in embryonic angiogenesis and vasculogenesis. |
| Purity | Greater than 90.0% as determined by SDS-PAGE. |
| Reagent Appearance | Sterile Filtered colorless liquid formulation. |
| Stability | Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of time. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).Avoid multiple freeze-thaw cycles. |
| Synonyms | Vascular endothelial growth factor B, VEGF-B, VRF, VEGFL, VEGF-related factor, VEGFB. |
